A predictive model for risk of early grade >= 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Dumontet, Charles | - |
dc.contributor.author | Hulin, Cyrille | - |
dc.contributor.author | Dimopoulos, Meletios A. | - |
dc.contributor.author | Belch, Andrew | - |
dc.contributor.author | Dispenzieri, Angela | - |
dc.contributor.author | Ludwig, Heinz | - |
dc.contributor.author | Rodon, Philippe | - |
dc.contributor.author | Van Droogenbroeck, Jan | - |
dc.contributor.author | Qiu, Lugui | - |
dc.contributor.author | Cavo, Michele | - |
dc.contributor.author | Van de Velde, Ann | - |
dc.contributor.author | Lahuerta, Juan Jose | - |
dc.contributor.author | Allangba, Olivier | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Boyle, Eileen | - |
dc.contributor.author | Perrot, Aurore | - |
dc.contributor.author | Moreau, Philippe | - |
dc.contributor.author | Manier, Salomon | - |
dc.contributor.author | Attal, Michel | - |
dc.contributor.author | Roussel, Murielle | - |
dc.contributor.author | Mohty, Mohamad | - |
dc.contributor.author | Mary, Jean Yves | - |
dc.contributor.author | Civet, Alexandre | - |
dc.contributor.author | Costa, Bruno | - |
dc.contributor.author | Tinel, Antoine | - |
dc.contributor.author | Gaston-Mathe, Yann | - |
dc.contributor.author | Facon, Thierry | - |
dc.date.available | 2020-02-27T10:41:52Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2018-06 | - |
dc.identifier.issn | 0887-6924 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3688 | - |
dc.description.abstract | Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections and study risk factors for TE grade >= 3 infection. The number of TE infections/month was highest during the first 4 months of treatment (defined as early infection). Of 1613 treated patients, 340 (21.1%) experienced TE grade >= 3 infections in the first 18 months and 56.2% of these patients experienced their first grade >= 3 infection in the first 4 months. Risk of early infection was similar regardless of treatment. Based on the analyses of data in 1378 patients through multivariate logistic regression, a predictive model of first TE grade >= 3 infection in the first 4 months retained Eastern Cooperative Oncology Group performance status and serum beta(2)-microglobulin, lactate dehydrogenase, and hemoglobin levels to define high-and low-risk groups showing significantly different rates of infection (24.0% vs. 7.0%, respectively; P < 0.0001). The predictive model was validated with data from three clinical trials. This predictive model of early TE grade >= 3 infection may be applied in the clinical setting to guide infection monitoring and strategies for infection prevention. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.relation.isPartOf | LEUKEMIA | - |
dc.subject | LENALIDOMIDE PLUS DEXAMETHASONE | - |
dc.subject | COMPLICATIONS | - |
dc.subject | METAANALYSIS | - |
dc.subject | MANAGEMENT | - |
dc.subject | DIAGNOSIS | - |
dc.subject | SURVIVAL | - |
dc.title | A predictive model for risk of early grade >= 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000434474100013 | - |
dc.identifier.doi | 10.1038/s41375-018-0133-x | - |
dc.identifier.bibliographicCitation | LEUKEMIA, v.32, no.6, pp.1404 - 1413 | - |
dc.identifier.scopusid | 2-s2.0-85047203048 | - |
dc.citation.endPage | 1413 | - |
dc.citation.startPage | 1404 | - |
dc.citation.title | LEUKEMIA | - |
dc.citation.volume | 32 | - |
dc.citation.number | 6 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | LENALIDOMIDE PLUS DEXAMETHASONE | - |
dc.subject.keywordPlus | COMPLICATIONS | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.